Wolchok, J. D. et al. General survival with mixed nivolumab and ipilimumab in superior melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
Ito, A., Kondo, S., Tada, Okay. & Kitano, S. Scientific growth of immune checkpoint inhibitors. BioMed. Res. Int. 2015, 605478 (2015).
Anderson, Okay. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell exercise: a case for synergistic therapies. Most cancers Cell 31, 311–325 (2017).
Shi, Y. et al. Subsequent-generation immunotherapies to enhance anticancer immunity. Entrance. Pharmacol. 11, 566401 (2020).
Mirlekar, B. & Pylayeva-Gupta, Y. IL-12 household cytokines in most cancers and immunotherapy. Cancers (Basel). 13, 167 (2021).
Del Vecchio, M. et al. Interleukin-12: organic properties and medical software. Clin. Most cancers Res. 13, 4677–4685 (2007).
Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146 (2003).
Nguyen, Okay. G. et al. Localized interleukin-12 for most cancers immunotherapy. Entrance Immunol. 11, 575597 (2020).
Moynihan, Okay. D. et al. Eradication of enormous established tumors in mice by mixture immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402–1410 (2016).
Mace, T. A. et al. IL-6 and PD-L1 antibody blockade mixture remedy reduces tumour development in murine fashions of pancreatic most cancers. Intestine 67, 320–332 (2018).
Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer native and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129–143 (2022).
Jorgovanovic, D., Music, M., Wang, L. & Zhang, Y. Roles of IFN-γ in tumor development and regression: a evaluation. Biomark. Res. 8, 49 (2020).
Hotz, C. et al. Native supply of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication throughout a number of preclinical tumor fashions. Sci. Transl. Med. 13, eabc7804 (2021).
Li, Y. et al. Multifunctional oncolytic nanoparticles ship self-replicating IL-12 RNA to eradicate established tumors and prime systemic immunity. Nat. Most cancers 1, 882–893 (2020).
Liu, J. Q. et al. Intratumoral supply of IL-12 and IL-27 mRNA utilizing lipid nanoparticles for most cancers immunotherapy. J. Management. Launch 345, 306–313 (2022).
Liu, M. A. A comparability of plasmid DNA and mRNA as vaccine applied sciences. Vaccines 7, 37 (2019).
Sangro, B. et al. Part I trial of intratumoral injection of an adenovirus encoding interleukin-12 for superior digestive tumors. J. Clin. Oncol. 22, 1389–1397 (2004).
Qiu, N. et al. Tumor-associated macrophage and tumor-cell dually transfecting polyplexes for environment friendly interleukin-12 most cancers gene remedy. Adv. Mater. 33, e2006189 (2021).
Hewitt, S. L. et al. Intratumoral IL12 mRNA remedy promotes TH1 transformation of the tumor microenvironment. Clin. Most cancers Res. 26, 6284–6298 (2020).
Aslan, C. et al. Exosomes for mRNA supply: a novel biotherapeutic technique with hurdles and hope. BMC Biotechnol. 21, 20 (2021).
Popowski, Okay. D. et al. Inhalable dry powder mRNA vaccines primarily based on extracellular vesicles. Matter 5, 2960–2974 (2022).
O’Brien, Okay., Breyne, Okay., Ughetto, S., Laurent, L. C. & Breakefield, X. O. RNA supply by extracellular vesicles in mammalian cells and its functions. Nat. Rev. Mol. Cell Biol. 21, 585–606 (2020).
Zickler, A. M. & El Andaloussi, S. Practical extracellular vesicles aplenty. Nat. Biomed. Eng. 4, 9–11 (2020).
Cheng, Okay. & Kalluri, R. Pointers for medical translation and commercialization of extracellular vesicles and exosomes primarily based therapeutics. Extracell. Vesicle 2, 100029 (2023).
Dinh, P. C. et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung restore in pulmonary fibrosis. Nat. Commun. 11, 1064 (2020).
Wang, Z. et al. Exosomes adorned with a recombinant SARS-CoV-2 receptor-binding area as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 6, 791–805 (2022).
Li, Z. et al. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung harm in a non-human primate mannequin of COVID-19. Nat. Nanotechnol. 16, 942–951 (2021).
Douguet, L. et al. A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat. Commun. 12, 653 (2021).
Casanova-Acebes, M. et al. Tissue-resident macrophages present a pro-tumorigenic area of interest to early NSCLC cells. Nature 595, 578–584 (2021).
Zhu, X. et al. Complete toxicity and immunogenicity research reveal minimal results in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J. Extracell. Vesicles 6, 1324730 (2017).
Mizrak, A. et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor development. Mol. Ther. 21, 101–108 (2013).
Kojima, R. et al. Designer exosomes produced by implanted cells intracerebrally ship therapeutic cargo for Parkinson’s illness therapy. Nat. Commun. 9, 1305 (2018).
Usman, W. M. et al. Environment friendly RNA drug supply utilizing crimson blood cell extracellular vesicles. Nat. Commun. 9, 2359 (2018).
Lieschke, G. J., Rao, P. Okay., Gately, M. Okay. & Mulligan, R. C. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor exercise in vivo. Nat. Biotechnol. 15, 35–40 (1997).
Tsai, S. J. et al. Exosome-mediated mRNA supply in vivo is secure and can be utilized to induce SARS-CoV-2 immunity. J. Biol. Chem. 297, 101266 (2021).
Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA supply and genome modifying. Nat. Biotechnol. 41, 1410–1415 (2023).
Gao, S., Wang, L., Liu, W., Wu, Y. & Yuan, Z. The synergistic impact of homocysteine and lipopolysaccharide on the differentiation and conversion of raw264.7 macrophages. J. Inflamm. 11, 13 (2014).
Mei, X. et al. An inhaled bioadhesive hydrogel to protect non-human primates from SARS-CoV-2 an infection. Nat. Mater. 22, 903–912 (2023).
Olivo Pimentel, V. et al. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when mixed with radiotherapy. J. Immunother. Most cancers 9, e001764 (2021).
Leonard, J. P. et al. Results of single-dose interleukin-12 publicity on interleukin-12-associated toxicity and interferon-gamma manufacturing. Blood 90, 2541–2548 (1997).
Chiocca, E. A. et al. Regulatable interleukin-12 gene remedy in sufferers with recurrent high-grade glioma: outcomes of a part 1 trial. Sci. Transl. Med. 11, eaaw5680 (2019).
Liu, Y. et al. Armored inducible expression of IL-12 enhances antitumor exercise of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J. Immunol. 203, 198–207 (2019).
Zhu, M. L., Nagavalli, A. & Su, M. A. Aire deficiency promotes TRP-1-specific immune rejection of melanoma. Most cancers Res. 73, 2104–2116 (2013).
Lizotte, P. H. et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic most cancers. Nat. Nanotechnol. 11, 295–303 (2015).
Gollob, J. A. et al. Part I trial of twice-weekly intravenous interleukin 12 in sufferers with metastatic renal cell most cancers or malignant melanoma: capacity to take care of IFN-gamma induction is related to medical response. Clin. Most cancers Res. 6, 1678–1692 (2000).
Smyth, M. J., Taniguchi, M. & Avenue, S. E. The anti-tumor exercise of IL-12: mechanisms of innate immunity which are mannequin and dose dependent. J. Immunol. 165, 2665–2670 (2000).
Xue, D. et al. A tumor-specific pro-IL-12 prompts preexisting cytotoxic T cells to regulate established tumors. Sci. Immunol. 7, eabi6899 (2022).
Karin, N. Chemokines within the panorama of most cancers immunotherapy: how they and their receptors can be utilized to show chilly tumors into scorching ones? Cancers 13, 6317 (2021).
Jones, D. S. 2nd et al. Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to boost the efficacy of adoptive T cell remedy. Sci. Adv. 8, eabi8075 (2022).
Rubinstein, M. P. et al. Ex vivo interleukin-12-priming throughout CD8(+) T cell activation dramatically improves adoptive T cell switch antitumor efficacy in a lymphodepleted host. J. Am. Coll. Surg. 214, 700–707 (2012).
Müller, J. M. et al. In vivo induction of interferon gamma expression in gray horses with metastatic melanoma ensuing from direct injection of plasmid DNA coding for equine interleukin 12. Schweiz Arch. Tierheilkd. 153, 509–513 (2011).
Goldszmid, R. S. et al. NK cell-derived interferon-γ orchestrates mobile dynamics and the differentiation of monocytes into dendritic cells on the web site of an infection. Immunity 36, 1047–1059 (2012).
Kerkar, S. P. et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol. Ther. 21, 1369–1377 (2013).
Geall, A. J. et al. Nonviral supply of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109, 14604–14609 (2012).
